7JUN

Cytospire's £61m oncology Series A oversubscribed

3 min read

10:09UTC

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May with the British Business Bank contributing £12m alongside international specialist funds.

← Back to OQC's £260m sets European quantum record Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Cytospire's oversubscribed £61m Series A at under three years old shows UK oncology attracts specialist international capital pre-clinical.

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May 2026. 4BIO Capital led the round; Servier Ventures, Abingworth, LifeArc Ventures, Sound Bioventures, and Medical Incubator Japan participated. The British Business Bank (BBB) contributed £12m, drawing on the direct-investment mandate that activated in April 2026, the same instrument behind the £40m Quantum Motion cornerstone . ¹

Cytospire's lead programme, CYT X300, is a first-in-class pan-gamma delta T cell engager targeting EGFR (Epidermal Growth Factor Receptor)-positive solid tumours. Existing cancer immunotherapy approaches typically target specific gamma delta T cell subtypes; CYT X300 targets all subtypes simultaneously, which is the mechanism the company claims distinguishes it clinically. Funds from the Series A go toward IND-enabling (Investigational New Drug) studies and Good Manufacturing Practice (GMP) manufacturing ahead of a first-in-human trial.

CellCentric closed its Series D on the same day, drawing exclusively private institutional capital from US and European healthcare funds, plus Pfizer as a strategic participant; Cytospire drew the BBB as a public co-investor alongside international specialist biotech funds. Two UK oncology rounds, one calendar day, two entirely different capital structures. The DSIT Life Sciences Innovative Manufacturing Fund had already allocated over £80m to four regional manufacturing sites on 14 April , signalling that DSIT-adjacent capital is entering life sciences at multiple points along the development chain. The BBB's presence in a sub-£100m Series A where private capital was already oversubscribing raises the additionality question the mandate was supposed to address: the fund is entering rounds where demand already exceeds supply, not rounds where private capital has declined to participate.

For UK oncology founders, the data point is the oversubscription at less than three years from incorporation: a first-in-class mechanism, no clinical data yet, and specialist international co-investors willing to lead. The BBB's £12m did not anchor the round; 4BIO Capital led it.

Deep Analysis

In plain English

Cytospire has developed a cancer treatment that works by recruiting a type of immune cell called gamma delta T cells to attack tumours. Existing cancer immunotherapies target specific subtypes of these cells; Cytospire's drug, CYT X300, is designed to engage all of them at once, potentially treating a wider range of patients with EGFR-positive solid tumours, a category that includes some lung, colorectal, and head and neck cancers. The company raised £61m in May 2026, just over three years after it was founded in London. The British Business Bank put in £12m alongside specialist cancer investment funds from the UK, France, Japan, and the US. The money funds safety testing studies and manufacturing preparation before the first clinical trial in humans.

Deep Analysis

Root Causes

The BBB's £12m contribution to an oversubscribed Series A illustrates the additionality question embedded in the new mandate.

Private capital led by 4BIO Capital and backed by Servier Ventures, Abingworth, and LifeArc Ventures had already pushed the round past its target. The BBB entered a round where private institutional appetite exceeded supply, which is the opposite of the seed-gap market failure the mandate was designed to address.

What could happen next?

Opportunity
Cytospire's international syndicate including Medical Incubator Japan positions the company for early Asian licensing discussions, a capital-efficient route to funding Phase 1 without requiring a US listing.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2016 to 2019 wave of UK CAR-T (chimeric antigen receptor T cell) companies, including Autolus Therapeutics (UCL spinout, listed on Nasdaq 2018), showed that British academic immunotherapy programmes can attract international Series A capital before clinical proof of concept when the mechanism is genuinely first-in-class.

Autolus raised £120m in its 2018 IPO on the strength of preclinical and Phase 1 data. Cytospire is following the same pattern at the same stage with a different T cell modality.

Counter-parallel: Kymera Therapeutics, a Boston immunotherapy company, raised $102m in a 2021 Series C on targeted protein degradation; its lead programme entered Phase 2 in 2023 but produced a clinical hold in 2024. First-in-class mechanism does not guarantee clinical success, and Cytospire's IND-enabling stage means investors are pricing in a multi-year clinical risk period with no human safety data yet.

At £61m Series A for a company incorporated in February 2023, Cytospire's implied post-money valuation positions it at the upper end of preclinical UK biotech, consistent with first-in-class mechanism pricing by specialist institutional funds.

The Japanese co-investor Medical Incubator Japan signals that Asian pharma groups are monitoring UK oncology immunotherapy for licensing optionality, which compresses the timeline to a potential non-dilutive licensing deal alongside the clinical programme.

Consensus view: 4BIO Capital's managing partners assess pan-gamma delta T cell engagers as a clinically distinct approach to solid tumour immunotherapy: unlike checkpoint inhibitors (pembrolizumab, nivolumab) which release existing T cell activity, CYT X300 recruits gamma delta T cells as effectors across the full heterogeneous population of EGFR-positive tumour subtypes.

The oversubscription at less than three years from incorporation reflects specialist investors pricing clinical optionality before Phase 1 data.

Counter-view: The Francis Crick Institute's immunology group notes that pan-gamma delta engagement has produced cytokine release syndrome in preclinical models. First-in-human trial design will require careful dose-escalation protocols, and the IND-enabling stage that Cytospire is funding carries significant safety risk before efficacy data exist.

Key tension: Whether pan-gamma delta T cell engagement can maintain tumour selectivity across heterogeneous patient populations without triggering systemic immune responses that limit the therapeutic window.

First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace (via GlobeNewswire)· 13 May 2026

Read original →

Causes and effects

Caused by

Business Bank begins direct startup investment

The BBB's £12m Cytospire co-investment is direct-mandate capital under the £6.6bn expansion activated in April 2026 (ID:2343).

Occurred 6 Apr 2026

Read story →

This Event

Cytospire's £61m oncology Series A oversubscribed

Cytospire's oversubscribed round at less than three years old shows that UK oncology immunotherapy companies with first-in-class mechanisms can attract large Series A rounds from international specialist capital, with public co-investment from the BBB entering rounds where private institutional appetite is already present.

Led to

State £50m backs the tier funds skip

The BBB's £12m into Cytospire (ID:3277) is part of the same £6.6bn direct mandate deployment that backstops Longwall Fund 4.

Occurred 27 May 2026

Read story →

IMU raises £40m to read blood

BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.

Occurred 2 Jun 2026

Read story →

Different Perspectives

Spanish state finance (COFIDES, CDTI)

Spain's COFIDES and CDTI have co-invested alongside UK deep-tech rounds in prior cycles and track the British Business Bank's direct-investment activity as a benchmark for state-capital deployment in innovation. BBB's two direct co-investments in one week set a pace reference for Iberian equivalents.

UK city-region mayors (Greater Manchester, West Midlands, Liverpool)

The LIPF devolution from 2027 hands seven mayors direct grant allocation, cutting Whitehall from the approval chain. Liverpool's £23.7m first allocation to AI research programmes shows the mechanism working before the formal devolution date.

Japanese strategic investors

OQC already generates hardware revenue in Japan, one of four countries where its quantum systems are live. Japan's national quantum strategy targets 2030 for commercial adoption; a UK supplier with active Japanese contracts is a supply-chain asset before domestic fabrication scales.

European venture capital (Highland Europe, Plural, Index Ventures)

European funds led or co-led three of the week's rounds: Highland Europe and Index Ventures on Wordsmith, Plural on Gigaton, Singular on Apoha. Continental LP capital is backing UK deep-tech and software at Series A and B without waiting for US validation.

US growth investors

Bullhound Capital's £260m OQC lead and DN Capital's £14.9m Airspeed ticket show US-linked growth capital treating UK quantum and AI as credible revenue bets rather than science projects. The OQC round is the largest-ever private quantum raise in Europe, suggesting US allocators have moved past post-Brexit risk discounts on UK technology.

UK Government (DSIT)

DSIT published Horizon recovery figures, Global Talent Fund recruitment numbers and the LIPF devolution announcement on overlapping days in June, framing a triple proof-point for its innovation agenda. The co-timing signals a deliberate narrative strategy linking talent, funding geography and international re-engagement into a single story.